MegaPro Biomedical , Ltd EBIT

MegaPro Biomedical , Ltd (6827.TWO) currently reports a EBIT of $-260M as of June 2026. That compares with $-250M in the prior-year period — down 2.2% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore MegaPro Biomedical , Ltd's EBIT history and peer comparisons.

MegaPro Biomedical , Ltd's EBIT decreased from $-250M to $-260M — a 2.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MegaPro Biomedical , Ltd's EBIT of $-260M is lower than the Healthcare sector average of $99B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

MegaPro Biomedical , Ltd reported $-260M in EBIT as of June 2026. That compares with $-250M in the prior-year period — down 2.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-260M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for MegaPro Biomedical , Ltd, and consider following 6827.TWO for alerts when major investors trade the stock.